赫巴林与Clostridioides difficile毒素相互作用的特征及其作为抗CDI治疗药物的潜力
Fuming Zhang1, Shaohui Wang2, Jiyuan Yang1
1Department of Chemical and Biological Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.
Carbohydrate polymers
|January 8, 2025
概括
克洛斯特里迪奥伊德困难毒素A和B强烈与肝素结合. 肝素是一种肝素.
科学领域:
- 微生物学 微生物学
- 生物化学 生物化学
- 分子生物学分子生物学
背景情况:
- 困难闭膜炎感染 (CDI) 是一种严重的医疗相关感染.
- 毒素A和B是CDI中关键的毒性因素.
- 硫酸糖氨基甘油 (GAG) 涉及C. difficile毒素进入细胞.
研究的目的:
- 为了研究肝素-毒素相互作用的结合动力学和结构要求.
- 为了阐明肝素在C. difficile毒素活性中的作用.
主要方法:
- 使用表面等离子体共振 (SPR) 来测量直接结合动力学.
- 进行了SPR竞争评估,以评估具有约束力的偏好.
- 进行了基于细胞的体外测试,以评估功能抑制.
主要成果:
- 毒素A和毒素B表现出高亲和度与肝素的结合 (KD = 3.3 nM和13.5 nM,分别).
- 毒素优先结合较长的肝素链.
- 肝素链的完全硫化对于毒素相互作用至关重要.
- 氨酸和非抗凝剂氨酸抑制了HeLa细胞中毒素A诱导的细胞圆化.
结论:
- 肝素与C. difficile毒素A和B的相互作用具有很高的亲和力.
- 肝素的特定结构特征,包括链条长度和硫化,对于结合至关重要.
- 氨酸显示出作为C. difficile毒素活性抑制剂的潜力.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
607
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
607
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
465
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
465
Combined Effects of Drugs: Synergism
3.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.7K
Factors Affecting Protein-Drug Binding: Drug Interactions
100
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
100
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114


